Table 5

Characteristics of the studies, pharmacokinetics and dose recommendations related to gentamicin

StudynPNAWeightStudy designGroupModelModalityAdministered doseVdCLt1/2 (hours)Recommended dose
Dodge et al,25 USA1137–42 PMA2.67–5.10P
1 group
Neonates and infants1-compartment with NPEMVV–VA2.5 mg/kg loading dose and every 8–12 hours maintenance doseFrom 0.748 L/kg to 0.471 L/kg after ECMO was discontinued
From 0.239 L/hour to 0.350 L/hour after ECMO was discontinued
From 9.24 hours to 3.87 hours after ECMO was discontinued
4.3 mg/kg loading dose
3.7 mg/kg every 18–24 hours of maintenance dose.
Moffett et al,22 USAN: 28
I: 5
0.17 (0.12–0.82) months3.1 (2.4–3.8)R
1 group
Mostly neonates and infants2-compartment with NONMEMVV–VA1.8 mg/kg/dose0.60 L/kg
0.03 L/kg/hour
Children with elevated serum creatinine values should have extended dosing intervals (4–5 mg/kg/day).
  • Boldfaced fonts represent comparisons with controls within the same study. In other studies, they represent comparisons with non-ECMO neonates from a different published study.

  • CL, clearance; ECMO, extracorporeal membrane oxygenation; I, infants; N, neonates; NONMEM, non-linear mixed-effects modelling; NPEM, non-parametric expectation and maximisation; P, prospective; PMA, postmenstrual age; PNA, postnatal age; R, retrospective; t1/2, elimination half-life; VA, veno-arterial; Vd, volume of distribution; VV, veno-venous.